NEW YORK – MRM Proteomics and Agilent Technologies said Thursday that they have entered a comarketing agreement for quantitative proteomics tools.
The partnership will cover Santa Clara, California-based Agilent's mass spectrometry products with Montreal-based MRM's kits for protein and metabolite quantitation.
MRM will develop assay kits specifically for Agilent's 6495 Triple Quad mass spec coupled to an Evosep One HPLC system. The company will also host in-person and virtual workshops on targeted quantitative proteomics workflows as well as the operation of the Evosep LC system.
"The new targeted proteomics workflows that have been developed through our collaboration with MRM Proteomics and Evosep will improve quantification of protein targets in clinical research and accelerate drug development in sample-limited environments," Jennifer Gushue, associate VP of mass spectrometry marketing at Agilent, said in a statement. "This collaboration highlights the capabilities of our 6495 LC/MS Triple Quadrupole as a winning combination with Evosep and MRM proteomics for targeted proteomics and our commitment to driving answers for the toughest analytical challenges."
Financial and other terms of the agreement were not disclosed.